Zevra Therapeutics, Inc.
ZVRA
$8.08
-$0.13-1.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.86% | 69.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.86% | 69.40% | |||
| Cost of Revenue | 820.37% | -1.54% | |||
| Gross Profit | -29.15% | 78.48% | |||
| SG&A Expenses | 6.33% | 20.83% | |||
| Depreciation & Amortization | 0.06% | -0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 48.31% | -6.18% | |||
| Operating Income | -129.93% | 65.22% | |||
| Income Before Tax | 4,111.79% | 90.59% | |||
| Income Tax Expenses | 86.04% | -92.31% | |||
| Earnings from Continuing Operations | 2,510.68% | 91.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2,510.68% | 91.33% | |||
| EBIT | -129.93% | 65.22% | |||
| EBITDA | -187.58% | 73.03% | |||
| EPS Basic | 2,263.35% | 91.43% | |||
| Normalized Basic EPS | -556.11% | 90.68% | |||
| EPS Diluted | 2,211.69% | 91.43% | |||
| Normalized Diluted EPS | -538.01% | 90.68% | |||
| Average Basic Shares Outstanding | 1.27% | 1.16% | |||
| Average Diluted Shares Outstanding | 4.12% | 1.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||